We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PD/PK Profiles of Insulin Biosimilar Should Mirror the Reference Product, EMA Says
PD/PK Profiles of Insulin Biosimilar Should Mirror the Reference Product, EMA Says
The European Medicines Agency is urging manufacturers of biosimilar insulin-containing products to demonstrate similar pharmacokinetic and pharmacodynamic profiles as the gold standard in proving efficacy similarity to their reference products.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor